<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: MEK is activated in ∼40% <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and 20-30% <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Selumetinib is a selective inhibitor of MEK1/2, which is currently in clinical development </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We evaluated the effects of selumetinib in vitro and in vivo in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> cell lines to identify <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell characteristics correlating with sensitivity to MEK inhibition </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> and six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were treated with selumetinib and classified according to the median inhibitory concentration (IC(50)) values as sensitive (≤1 μM) or resistant (&gt;1 μM) </plain></SENT>
<SENT sid="4" pm="."><plain>In selumetinib-sensitive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines, selumetinib treatment induced G1 cell-cycle arrest and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and suppression of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> as xenografts in immunodeficient mice </plain></SENT>
<SENT sid="5" pm="."><plain>Evaluation of intracellular effector proteins and analysis of gene mutations showed no correlation with selumetinib sensitivity </plain></SENT>
<SENT sid="6" pm="."><plain>Microarray gene expression profiles revealed that the activation of cAMP-dependent protein kinase A (PKA) was associated with MEK inhibitor resistance </plain></SENT>
<SENT sid="7" pm="."><plain>Combined targeting of both MEK and PKA resulted in <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e> inhibition of MEK inhibitor-resistant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines in vitro and in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: This study provides molecular insights to explain resistance to an MEK inhibitor in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
</text></document>